Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split



  Celgene Corporation Board of Directors Recommends to Our Stockholders a
  Two-for-One Stock Split

Business Wire

SUMMIT, N.J. -- February 13, 2014

Celgene Corporation (NASDAQ:CELG) announced that the Board of Directors voted
to recommend a two-for-one split of the Company’s common stock to be effected
through an Amendment to the Company’s Certificate of Incorporation.

“This recommendation reflects our continued confidence in the long-term
outlook for the Company,” said Bob Hugin, Chairman and Chief Executive Officer
of Celgene Corporation.

Implementation of the stock split is subject to stockholder approval of the
Amendment at the Annual Meeting of Stockholders, which is currently scheduled
to take place on June 18, 2014. Additional details regarding the annual
meeting and the proposed amendment will be included in a proxy statement
distributed to stockholders on or before April 30, 2014.

If the Amendment is approved, the stock split will become effective on the
date the Amendment is filed with the Secretary of State of the State of
Delaware. Total shares outstanding are expected to increase from approximately
406 million to approximately 812 million. The average weighted diluted shares
outstanding for 2014 are expected to increase from approximately 425 million
to approximately 850 million.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceutical company engaged primarily in the discovery,
development and commercialization of novel therapies for the treatment of
cancer and inflammatory diseases through gene and protein regulation. For more
information, please visit www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking statements can be
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans," "will," “outlook” and similar expressions.
Forward-looking statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are made. We
undertake no obligation to update any forward-looking statement in light of
new information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and uncertainties, most of
which are difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of factors,
many of which are discussed in more detail in our Annual Report on Form 10-K
and our other reports filed with the Securities and Exchange Commission.

Contact:

Celgene Corporation
Jacqualyn A. Fouse, PhD, 908-673-9956
EVP, Chief Financial Officer
or
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement